The AST/ALT ratio predicts survival and improves oncological therapy decisions in patients with non-small cell lung cancer receiving immunotherapy with or without radiotherapy.

For patients with a pre-treatment AST/ALT ratio <0.67, despite the comparison between ICIs-nonRT and iRT ( P =0.073) not reaching statistical significance, a clear trend could be discerned ( Figure 3F ).

also in 19,460 other papers